XXXX induced responses are attenuated by a cannabinoid receptor agonist in @entity1 skin.

@entity1 @entity10025 @entity112
OBJECTIVE AND DESIGN: In the present study we examined the effects of the cannabinoid receptor agonist @entity10025 on @entity112 -evoked somatosensory and vascular responses in @entity1 . SUBJECTS: Two sets of experiments were performed, in which twelve (Study 1, iontophoresis) and six @entity1 (Study 2, microdialysis) were recruited. TREATMENT: @entity10025 was administered peripherally by skin patch (50 mM) or dermal microdialysis (5 mM), whereas @entity112 was applied by iontophoresis (50 microAmps) or dermal microdialysis (5 microM). METHODS: Skin blood flow was monitored by laser Doppler, widespread flare reaction was evaluated planimetrically, extravasation of plasma proteins was measured in the dialysate and perceived itch was recorded using a visual analogue scale. Data were evaluated by analysis of variance. RESULTS: Experimentally induced itch was significantly reduced by peripheral administration of @entity10025 (p < 0.05). Additionally, skin blood flow and neurogenic mediated flare responses were attenuated (p < 0.003 and p < 0.03, respectively), whereas protein extravasation due to @entity112 was enhanced by co-administration of @entity10025 , as investigated by dermal microdialysis. CONCLUSIONS: In @entity1 peripheral administration of a cannabinoid receptor agonist attenuates @entity112 -induced itch. The observation that protein extravasation was not decreased demonstrates that the alleviation of itch is not due to an anti-histaminergic property of @entity10025 . The reduced neurogenic flare reaction indicates an attenuated antidromic nerve fibre activation and neuropeptide release.
